+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Diabetic Retinopathy - Epidemiology Forecast to 2029

  • ID: 5142170
  • Report
  • August 2020
  • Region: Global
  • 48 pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

Diabetic retinopathy is a sight-threatening microvascular eye complication of type 1 and type 2 diabetes, and is a leading cause of preventable visual disability and blindness in working-age adults throughout the world (Rubino et al., 2007). Only those with diabetes are at risk for diabetic retinopathy. Characteristically asymptomatic, diabetic retinopathy has few recognizable ophthalmic symptoms until the onset of actual visual loss (Fong et al., 2004). The pathophysiology of diabetic retinopathy stems from damage to the microvasculature of the retina due to prolonged metabolic changes induced by poorly managed diabetes (Williams et al., 2004).

The publisher epidemiologists utilized historical data obtained from peer-reviewed articles and population-based studies to build forecast for the diagnosed prevalent cases of diabetic retinopathy, diagnosed prevalent cases of DME, and diagnosed prevalent cases of RVO in the 9MM. The publisher's epidemiologists applied the prevalence of diabetic retinopathy, DME, and RVO drawn from the above sources to each country’s population to calculate the number of estimated diagnosed prevalent cases for diabetic retinopathy, DMV, and RVO respectively.

The following data describes the epidemiology of diabetic retinopathy. In the 9MM, the diagnosed prevalent cases of diabetic retinopathy are expected to increase from 14,267,247 cases in 2019 to 17,750,520 cases in 2029, at an Annual Growth Rate (AGR) of 2.44%. In 2029, China will have the highest number of diagnosed prevalent cases of diabetic retinopathy in the 9MM, with 6,975,178 diagnosed prevalent cases, whereas Australia will have the fewest diagnosed prevalent cases with 515,181 cases. In the 9MM, the diagnosed prevalent cases of RVO are expected to increase from 13,292,153 cases in 2019 to 15,722,813 cases in 2029, at an AGR of 1.83%.

Scope
  • The Diabetic Retinopathy Epidemiology Report provides an overview of the risk factors and global trends of Diabetic Retinopathy in the nine major markets (9MM: US, France, Germany, Italy, Spain, UK, Japan, Australia, and China).
  • The report includes a 10-year epidemiology forecast for the diagnosed prevalent cases of diabetic retinopathy, diagnosed prevalent cases of diabetic macular edema (DME), and diagnosed prevalent cases of retinal vein occlusion (RVO).
  • The diagnosed prevalent cases of diabetic retinopathy are segmented by age (20 years and older), sex, and severity (mild NPDR, moderate NPDR, severe NPDR, and PDR). Additionally, the RVO cases are segmented by age, sex, and type (branch retinal vein occlusion [BRVO] and central retinal vein occlusion [CRVO]). This epidemiology forecast also provides clinically significant macular edema (CSME) among the DME population, macular edema following BRVO, and macular edema following CRVO.
  • The diabetic retinopathy epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 9MM.
Reasons to Buy

The Diabetic Retinopathy Epidemiology series will allow you to -
  • Develop business strategies by understanding the trends shaping and driving the global diabetic retinopathy markets.
  • Quantify patient populations in the global diabetic retinopathy markets to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for diabetic retinopathy therapeutics in each of the markets covered.
  • Understand magnitude of diabetic retinopathy population by its severity.
Note: Product cover images may vary from those shown
1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Diabetic Retinopathy: Executive Summary
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Reports

3 Epidemiology
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global and Historical Trends
3.4 Forecast Methodology
3.4.1 Sources
3.4.2 Forecast Assumptions and Methods
3.4.3 Forecast Assumptions and Methods: Diagnosed Prevalent Cases of Diabetic Retinopathy
3.4.4 Forecast Assumptions and Methods: Diagnosed Prevalent Cases of Diabetic Retinopathy by Severity
3.4.5 Forecast Assumptions and Methods: Diagnosed Prevalent Cases of RVO
3.4.6 Forecast Assumptions and Methods: Diagnosed Prevalent Cases of DME
3.4.7 Forecast Assumptions and Methods: Diagnosed Prevalent Cases of Macular Edema Following BRVO
3.4.8 Forecast Assumptions and Methods: Diagnosed Prevalent Cases of Macular Edema Following CRVO
3.4.9 Forecast Assumptions and Methods: Diagnosed Prevalent Cases of CSME
3.5 Epidemiological Forecast for Diabetic Retinopathy (2019-2029)
3.5.1 Diagnosed Prevalent Cases of Diabetic Retinopathy
3.5.2 Age-Specific Diagnosed Prevalent Cases of Diabetic Retinopathy
3.5.3 Sex-Specific Diagnosed Prevalent Cases of Diabetic Retinopathy
3.5.4 Sex-Specific Diagnosed Prevalent Cases of Diabetic Retinopathy by Severity
3.5.5 Diagnosed Prevalent Cases of RVO
3.5.6 Age-Specific Diagnosed Prevalent Cases of RVO
3.5.7 Sex-Specific Diagnosed Prevalent Cases of RVO
3.5.8 Diagnosed Prevalent Cases of DME in the Diabetic Retinopathy Population
3.5.9 Diagnosed Prevalent Cases of Macular Edema Following BRVO
3.5.10 Diagnosed Prevalent Cases of Macular Edema Following CRVO
3.5.11 Diagnosed Prevalent Cases of CSME in the DME Population
3.6 Discussion
3.6.1 Epidemiological Forecast Insight
3.6.2 Coronavirus Disease 2019 (COVID-19) Impact
3.6.3 Limitations of the Analysis
3.6.4 Strengths of the Analysis

4 Appendix
4.1 Bibliography
4.2 About the Authors
4.2.1 Epidemiologist
4.2.2 Reviewers
4.2.3 Global Director of Therapy Analysis and Epidemiology
4.2.4 Global Head and EVP of Healthcare Operations and Strategy
4.3 About the Publisher
4.4 Contact
4.5 Disclaimer

List of Tables
Table 1: Summary of Newly Added Data Types
Table 2: Summary of Updated Data Types
Table 3: Risk Factors and Comorbidities for Diabetic Retinopathy

List of Figures
Figure 1: 9MM, Diagnosed Prevalent Cases of Diabetic Retinopathy, Both Sexes, N, Ages ≥20 Years, 2019 and 2029
Figure 2: 9MM, Diagnosed Prevalent Cases of RVO, Both Sexes, N, Ages ≥20 Years, 2019 and 2029
Figure 3: 9MM, Diagnosed Prevalence of Diabetic Retinopathy Among the Diagnosed Diabetics Population, Both Sexes, %, Ages ≥20 Years, 2019
Figure 4: 9MM, Diagnosed Prevalence of RVO in the General Population, Both Sexes, %, Ages ≥20 Years, 2019
Figure 5: 9MM, Sources Used and Not Used, Diagnosed Prevalent Cases of Diabetic Retinopathy
Figure 6: 9MM, Sources Used and Not Used, Diagnosed Prevalent Cases of RVO
Figure 7: 9MM, Sources Used and Not Used, Diagnosed Prevalent Cases of Diabetic Retinopathy by Severity
Figure 8: 9MM, Sources Used and Not Used, Diagnosed Prevalent Cases of Diabetic Macular Edema
Figure 9: 9MM, Sources Used, Diagnosed Prevalent Cases of Macular Edema Following BRVO
Figure 10: 9MM, Sources Used, Diagnosed Prevalent Cases of Macular Edema Following CRVO
Figure 11: 9MM, Sources Used, Diagnosed Prevalent Cases of CSME
Figure 12: 9MM, Diagnosed Prevalent Cases of Diabetic Retinopathy, N, Both Sexes, Ages ≥20 Years, 2019
Figure 13: 9MM, Age-Specific Diagnosed Prevalent Cases of Diabetic Retinopathy, N, Both Sexes, 2019
Figure 14: 9MM, Diagnosed Prevalent Cases of Diabetic Retinopathy by Sex, N, Ages ≥20 Years, 2019
Figure 15: 9MM, Diagnosed Prevalent Cases of Diabetic Retinopathy by Severity, N, Ages ≥20 Years, 2019
Figure 16: 9MM, Diagnosed Prevalent Cases of RVO, Both Sexes, N, Ages ≥20 Years, 2019
Figure 17: 9MM, Diagnosed Prevalent Cases of RVO by Age, N, Both Sexes, 2019
Figure 18: 9MM, Diagnosed Prevalent Cases of RVO by Sex, N, Ages ≥20 Years, 2019
Figure 19: 9MM, Diagnosed Prevalent Cases of DME in the Diabetic Retinopathy Population, N, Ages ≥20 Years, Both Sexes, 2019
Figure 20: 9MM, Diagnosed Prevalent Cases of Macular Edema Following BRVO, Both Sexes, N, Ages ≥20 Years, 2019
Figure 21: 9MM, Diagnosed Prevalent Cases of Macular Edema Following CRVO, Both Sexes, N, Ages ≥20 Years, 2019
Figure 22: 9MM, Diagnosed Prevalent Cases of CSME in the DME Population, N, Both Sexes, Ages ≥20 Years, 2019
Note: Product cover images may vary from those shown
Adroll
adroll